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Abstract
Many crucial cellular processes are regulated by signaling and trafficking pathways, which are
largely dependent on protein interactions in the cell. These networks are thought to play a crucial
role in the evolution of multicellular organisms from their unicellular ancestors.
Choanoflagellates are unicellular organisms that can adopt a multicellular state, called a rosette.
Though they evolved independently from and prior to the diversification of metazoans, they are
the closest extant nonmetazoan ancestor to animals, making them a compelling model for the
study of early multicellularity. Here, we look at two structurally conserved peptide-binding
domains that both play important roles in cellular signaling and trafficking. PDZ and SH2
domains are peptide-binding domains that have highly conserved structures and are found in
humans and choanoflagellates. We analyzed the binding cleft of a non-homologous PDZ domain
and compared the binding affinities of that PDZ domain to two human PDZ domains. We also
developed a program that looks specifically at the PDZ binding cleft and finds the most similar
human PDZ domain to an uncharacterized choanoflagellate PDZ domain, then finds potential
endogenous target sequences of the uncharacterized PDZ domain. To assess conservation of
PDZ domain structure we solved high-resolution crystal structures of a representative M.
brevicollis PDZ domain that is homologous to human Dlg1 PDZ2. We also studied the binding
cleft of a conserved SH2 domain from the TEC family of kinases. Overall, we find that
interactions between the domain and non-motif residues dramatically influence peptide binding
and, using our program, we can begin to predict successful interactions. The evolutionary
conservation of PDZ and SH2 domain makes them ideal candidates to study to better understand
how the evolution of signaling and trafficking domains and pathways coincided with the
emergence of multicellularity.
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Introduction
Choanoflagellates are microscopic aquatic organisms recognized as the closest living
ancestor of metazoans and unicellular eukaryotes, although they evolved independently from and
prior to the diversification of metazoans (Figure 1).1,2 Uniquely, choanoflagellates are
unicellular, but capable of adopting a primitive multicellular state called a rosette via serial
rounds of cell division.3,4 Studying these rosettes provides an interesting model for studying the
development and evolution of animal multicellularity.1 Several gene families are shared between
metazoans and choanoflagellates, many of which are differentially expressed during the
development of the rosette. In fact, 350 gene families that were previously thought to be present
only in animals also exist in choanoflagellates.5 In this study, we focus on Monosiga brevicollis.

Figure 1. Phylogenetic tree showing the close relationship between M. brevicollis and metazoa.

M. brevicollis has genes that are almost as intron-rich as human genes, although short in
comparison to metazoan introns.1 The genome of M. brevicollis reveals 78 protein domains
exclusive to choanoflagellates and metazoans.1 Many of the domains that are responsible for
signaling and trafficking are found abundantly in the M. brevicollis proteome.1 Two of these
domains are discussed herein: PDZ domains and SH2 domains.1,6 Both of these domain types
evolved prior to the separation of the choanoflagellate and metazoan lineages and have
proliferated in the metazoan lineage since that separation. Although present in both

choanoflagellates and metazoans, the functions they serve in these branches of evolution may be
distinct. According to UniProt annotations, for example, there are no human PDZ domaincontaining proteins that also contain SH2 domains, whereas in M. brevicollis there are five
(Figure 2, Table S 5). This further suggests that the distinct function PDZ domains and SH2
domains play in signaling systems of choanoflagellates and metazoans became increasingly
disparate as these two organisms were separated by millions of years of evolution.

Figure 2. Protein domain architecture schematics for several M. brevicollis PDZ domain‐containing proteins, based
on UniProt annotations with one exception (see below). Colors represent different domains, black = PDZ domains
(numbered), light blue = SH3, purple = guanylate kinase (labeled Guan_Kinase), yellow = ankyrin repeat region
(ANK_region), pink = tyrosine phosphatase (Tyr_Phosphatase), light green = SH2, orange = SAM, and dark red =
FERM. Note: A9V1Y4 PDZ1 is a novel PDZ domain (not annotated as such in UniProt) based on Rosetta modeling
(Figure S 2).

The transition to multicellularity is an area of current investigation and by comparing M.
brevicollis and metazoan signaling and trafficking pathways, we can begin to piece together the
complex underpinnings of metazoan evolution.1 To study these questions on a molecular level,
we studied both homologous and non-homologous PDZ domains.
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I analyzed the binding cleft of a non-homologous PDZ domain in comparison to two
human PDZ domains from DLG1 PDZ1 and synaptojanin-2-binding protein. PDZ domains have
previously been shown to have a structurally conserved binding cleft.4 Here, I look at seven of
those conserved residues to determine if we can predict the peptide binding of an uncharacterized
M. brevicollis PDZ domain based on the identities of those residues. To aid in this effort, we
developed a program to predict peptide binding of non-homologous PDZ domains based on their
similarities to characterized human PDZ domains. The program then uses the known peptide
binding targets of those human PDZ domains to predict endogenous targets of the M. brevicollis
PDZ domain.
I also crystallized a homolog of the PDZ domain of human DLG found in M. brevicollis.
The structural characterization of this protein showed only two very conservative differences in
binding site residues between the choanoflagellate and human PDZ domain.
Finally, I looked at homologous SH2 domains from TEC family kinases found in both
humans and M. brevicollis. These domains also have a conserved structure, but their selectivity
is influenced greatly by the presence of a phosphorylated tyrosine and regulated by the EF and
BG loops. I expressed and purified these domains in an attempt to compare peptide selectivity
between the human and M. brevicollis homologue.

3

Chapter 1: Biochemical characterization and computational analysis of non-homologous
PDZ domains in Monosiga brevicollis
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1.1 Introduction: PDZ Domains
PDZ domains are peptide binding domains crucial in a variety of cell signaling networks.
They are one of several gene families shared between metazoans and choanoflagellates. These
domains, named for the first PDZ-domain containing proteins identified (PSD-95, Dlg1, and
ZO-1), are particularly interesting to study for a number of reasons.7 The intercellular
attachments that are formed during choanoflagellate rosette development are reminiscent of
metazoan neuronal synapses. PDZ domains are also overrepresented in the choanoflagellate
genome and have been shown to have proliferated in the metazoan lineage.4 This suggests that
PDZ domains played a role in the evolution of multicellularity and that studying PDZ domains
may provide insight into the development of early multicellularity.
PDZ domains are protein domains that serve the basic function of scaffolding proteinprotein interactions. They are found in a variety of organisms including mammals, yeast, plants,
and bacteria.7 PDZ domains have a key “GLGF” amino acid sequence which forms a loop; the
amide backbone of that loop interacts with the carboxylate atoms of the ligand’s C-terminus
(Figure 3A). PDZ domains are 80-100 amino acid residues in length and have a conserved
structural fold containing a core antiparallel β-sheet and one or two ɑ-helices (Figure 3B). These
domains bind to short sequences on the ligand, often of only six amino acids. The classical motif
of PDZ domains is dictated by two residues, the extreme C-terminal residue, called P0, and P-2,
which is two residues adjacent.4 Class I PDZ domains, for example, recognize the motif X-S/TX-φ (where X=any amino acid and φ=any hydrophobic amino acid) at the C-terminus of target
proteins. Previously, these two specific residue positions were thought to be entirely responsible
for targeted binding to the PDZ domain. Work using high throughput techniques such as phage
display, peptide array, and hold-up assay has altered this view to recognize the significance of
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non-motif residue interactions.8 Protein engineering studies have also identified structural
elements that affect PDZ selectivity.9,10

Figure 3. Conserved PDZ domain structure. (A) Conserved GLGF loop of PDZ domain. Human DLG1 PDZ2 (PDB
ID: 4G69) is shown in cartoon representation, with the conserved GLGF loop in stick, colored blue, and labeled.
Bound peptide is in orange stick. C-terminus of ligand is labeled. (B) PDZ domain structure showing antiparallel βsheets in pale cyan cartoon, ɑ-helices in dark teal cartoon, and peptide in orange stick.

Recent work has shown that homologous proteins in choanoflagellates and humans
usually share evolutionarily conserved residues responsible for non-motif binding specificity,
despite a lack of conservation in shared target proteins.4 In this case, it is relatively
straightforward to determine high affinity binding peptides in the choanoflagellate as the high
degree of conservation means those will be the same sequences as in humans. However, not all
PDZ domains in the choanoflagellate have a human homologue. To study the binding
interactions of those non-homologous PDZ domains, high affinity peptides would need to be
developed and then found in the choanoflagellate proteome. This process often requires
6

techniques such as phage display or high-throughput screens, as previously mentioned studies
used. These techniques are not only costly, but they require both protein and specialized lab
materials. While these high throughput techniques allow researchers to find the highest affinity
binders for a given PDZ domain, this does not necessarily correspond to the peptide sequence of
the endogenous interaction. Therefore, there is no guarantee that these techniques would allow us
to identify cellular signaling networks.
In this study, I wanted to know if I could computationally find the highest affinity
binding partner for a previously uncharacterized PDZ domain found only in M. brevicollis. To do
so, we developed a program that looks at the binding cleft residues in this PDZ domain and
compares them to a database of human PDZ domains with known peptide interactions,
effectively allowing us to find an endogenous target sequence for the non-homologous M.
brevicollis PDZ domain. Here, I verify the efficacy of this program by testing the binding of this
non-homologous PDZ domain with the peptides we computationally determined to be the highest
affinity binders.

7

1.2 Results
1.2.1 Structural and biochemical characterization of A9UPE9 PDZ.
To test the peptide binding of a non-homologous choanoflagellate PDZ domain, I first
needed to find a PDZ domain with no clear human homologue. We looked at several PDZ
domains (UniProt IDs: A9UPE9 PDZ; A9V9U8 PDZ 1, A9V9U8 PDZ 2, A9V9U8 PDZ 3;
A9V7X5 PDZ; A9UZP0 PDZ 3, A9UZP0 PDZ 8, A9UZP0 PDZ 17). Several of these PDZ
domains were not amenable to recombinant expression and purification using Escherichia coli,
which is an issue we are continuing to troubleshoot.
One PDZ domain I was able to express and purify is from the protein A9UPE9. A9UPE9,
is a 545 amino acid protein with a PDZ domain (residues 12-99) and an SH3 domain (residues
130-191). A9UPE9 PDZ and INADL PDZ from the human proteome, the closest sequence
alignment, share only a 45.33% sequence identity over 98% of the PDZ domain (Table 1). The
full INADL protein does not have an SH3 domain, but a L27 domain, as well as 10 PDZ
domains, meaning that while the PDZ domains are likely related, the full-length proteins are not
homologous.
Table 1. Sequence identity values of A9UPE9 PDZ and human PDZ domains.

GRIP2

GRIP1

Scribble,
Chain A

lin-7

MAGI3

MPDZ 12th
PDZ

MAGI1

BAI1

Synaptojanin2-binding
protein

A9UPE9
PDZ

INADL

Sequence identity (query cover)

45.33%
(98%)

41.37%
(96%)

40.54%
(96%)

40.51%
(87%)

39.53%
(97%)

38.10%
(98%)

37.35%
(94%)

35.87%
(95%)

35.48%
(95%)

34.44%
(96%)

I expressed and purified A9UPE9 PDZ using previously described methods, and as
described in further detail in the Materials and Methods. Briefly, I used recombinant expression

8

in E. coli cells, followed by affinity and size exclusion chromatography to produce purified
A9UPE9 PDZ. Then, I crystallized A9UPE9 PDZ with the HPV16 E6 peptide, as described in
the Materials and Methods and Supplementary Information.

1.2.2 Binding experiments of A9UPE9 PDZ and DLG1 PDZ1.
PDZ domains have a highly conserved fold, and we know that the residues that exist
within that fold affect the binding selectivity of the domain. Specifically, that residues on the
PDZ domain are interacting with the non-motif residues on the peptide and influencing the
specificity of that interaction. Thus, I wanted to know whether we could predict what
endogenous peptides would bind most favorably to A9UPE9 PDZ based on similarities of seven
residues positioned to affect the binding cleft (Figure 4). We did this in two ways: manually and
computationally.

Figure 4. A9UPE9 PDZ homology model with seven binding site residues shown in cyan stick and highlighted in
cyan on sequence. These seven residues are positioned to affect non-motif binding selectivity of PDZ domains.
Peptide shown in orange stick.

9

Manually, I generated a list of human PDZ domains and listed the seven residues in those
crucial positions for each of those PDZ domains. I then compared the seven amino acids in
A9UPE9 PDZ at those positions to the generated list to find the PDZ domain with the highest
similarity in binding site residues. In this case, that was the DLG (disks large) family of PDZ
domains. We can then predict, due to the degree of similarity in the binding cleft between these
two PDZ domains, that the peptides that bind DLG PDZ domains will also bind A9UPE9 PDZ.
To test this hypothesis, I studied two known DLG1 PDZ1 binding targets: HPV16 E6
(sequence: SSRTRRETQL) and HPV18 E6 (sequence: RLQRRRETQV). I also studied four
peptides (sequences: SRETTV, SRETDV, RRETTV, and RRETDV) similar to known DLG
family binding targets.11 I made mutations at specific positions to allow us to pinpoint which
changes are, or are not, tolerated. Then, I calculated the binding affinities of these peptides using
fluorescence polarization. I first measured the binding affinity of both A9UPE9 PDZ and DLG1
PDZ1 for a decameric fluorescent reporter peptide (F*-RLQRRRETQV, where F*=FITC of
fluorescein isothiocyanate), calculating a KD = 6.9 ± 1.7 µM in a triplicate experiment (Figure
8C and Figure 8D). Next, I determined the affinities of the six peptides listed previously using
competition experiments (Figure 5). In comparison to DLG1 PDZ1, I found A9UPE9 PDZ
bound less tightly to all peptides except RRETDV and SRETDV, to which it bound equally
tightly (Table 3, Table S 2). Experimental protocols were based on previously described methods
and are described in more detail in the Materials and Methods.4,12–15
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Competition Experiments A9UPE9 PDZ
0.25
0.23
0.21

Anisotropy

0.19
0.17
0.15
0.13
0.11
0.09

SRETTV
SRETDV
RRETTV
RRETDV
HPV16e6
HPV18e6

0.07
-9

-8

-7

-6

-5

log([peptide]/M)

-4

-3

-2

0.05

Figure 5. Competition experiment data of A9UPE9 PDZ with F*- HPV18 E6 reporter peptide.

Given this data, we decided to develop a program that would tackle this program with the
goal of yielding endogenous peptides that would bind more tightly than what I was able to
achieve manually. Hence, we wrote a program, Domain Analyzer and Motif Matcher (DAMM),
that takes in a single FASTA file from a PDZ domain of interest as input and outputs the top npercent best matching human PDZ domains, where n is user specified. To accomplish this,
DAMM first performs a pairwise BLAST alignment with 141 of our labeled human PDZ
sequences before presenting the top result (in terms of percent identity match) to the user (Table
S 4). After presenting this result, the user inputs the index of each of the seven conserved
residues from the input sequence. DAMM proceeds to align the rest of the human PDZ domains,
and subsequently scores the conserved residues in all aligned sequences. A residue can exist in
three states: (1) matching the input sequence in absolute terms, (2) matching the input sequence
through characteristics, or (3) not matching it at all (which may include a gap or a mismatch).
11

Finally, DAMM displays to the user the top scoring matches sorted in a stepwise manner by
absolute score, then characteristic score, and finally alignment identity score. So, for example, if
A9UPE9 PDZ had a valine at a certain position, an isoleucine substitution would rank higher
than a lysine substitution.

Figure 6. Flow chart showing DAMM as a stepwise process. DAMM allows the user to input an unknown PDZ
domain sequence and receive an output of human PDZ domains ranked by binding cleft similarity.

While this accomplishes the domain analysis portion of the program, DAMM also
integrates with Motif Matcher 2.0, the second version of a program we previously published.13
Given certain inputs (a proteome, position constraints, a substitution limit, and a target motif),
this Motif Matcher provides a simple, yet efficient, method to extract similar motifs in the source
proteome.10,13 Combined with the domain analysis portion of our tool, we provide a user-
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friendly and efficient program that displays similarity measurements about a protein, as well as
potential endogenous targets, given only it’s FASTA sequence.

Table 2. Domain Analyzer alignment scores of A9UPE9 PDZ with human PDZ domains.

DLG1 PDZ2

DLG2 PDZ2

DLG4 PDZ2

MPDZ PDZ12

DLG3 PDZ2

DLG1 PDZ1

DLG2 PDZ1

DLG4 PDZ1

DLG3 PDZ1

A9UPE9
PDZ

SYNJ2BP

Alignment Score % (identity matches/characteristic matches)

31%
(5/2)

29%
(4/2)

29%
(4/2)

29%
(4/2)

32%
(4/2)

30%
(4/2)

30%
(4/2)

29%
(4/2)

29%
(4/2)

30%
(4/2)

DAMM flagged a different PDZ domain as having the highest similarity to A9UPE9
PDZ: Synaptojanin-2-binding protein PDZ (SYNJ2BP PDZ) (UniProt ID: P57105). The DLG
family of PDZ domains was also highly ranked, with only one less identity match than SYNJ2BP
PDZ (Table 2). DLG1 PDZ1, the PDZ domain I manually determined to be high similarity to
A9UPE9 PDZ, had an alignment score of 30% with four identity matches and two characteristic
matches, implying that DLG1 PDZ1 binding targets should still bind A9UPE9 PDZ quite well,
which is consistent with what we see in our binding studies.

Figure 7. Sequence alignment of A9UPE9 PDZ, SYNJ2BP PDZ, and DLG1 PDZ1. Seven binding site residues
bolded and shown in teal font for identity match and orange font for characteristic match.
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Figure 8. (A) Homology model alignment of A9UPE9 PDZ and DLG1 PDZ1 (PDB ID: 3RL7). Peptide shown in
orange stick. A9UPE9 PDZ binding site residues shown in cyan stick. DLG1 PDZ1 binding site residues shown in
salmon stick. (B) Alignment of A9UPE9 PDZ and SYNJ2BP PDZ (PDB ID: 2JIK). Peptide shown in orange stick.
A9UPE9 PDZ binding site residues shown in cyan stick. SYNJ2BP PDZ binding site residues shown in violet stick.
(C) KD of A9UPE9 PDZ with F*-HPV18 E6, where the black, blue, and red lines are trials 1, 2, and 3, respectively.
(D) KD of DLG1 PDZ1 with F*-HPV18 E6, where the black, blue, and red lines are trials 1, 2, and 3, respectively.
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I wanted to see if I could find a more favorable endogenous binding target for A9UPE9
PDZ by looking at peptides that bind to SYNJ2BP PDZ. To determine which peptides to test, I
first did a literature search to find peptides that are known to bind to SYNJ2BP PDZ.16–18 We
then used Motif Matcher to determine which of those sequences have related sequences in the M.
brevicollis proteome (Table S 1). 10,13 This yielded six peptides of interest: SRRTEV, STRSDV,
VIATEV, HRESTV, RLASEV, and GSESSV. Competition experiments of SRRTEV and
STRSDV, done with only A9UPE9 PDZ, revealed binding affinities of greater than 1000 μM
(Table 3). Testing of the remaining four peptides is ongoing.
Table 3. A9UPE9 and DLG1 PDZ1 Ki values.

†

Standard deviations were not calculated for Ki values greater than 1000 μM.

We expected the six initial peptides we tested (SRETTV, SRETDV, RRETTV,
RRETDV, HPV16 E6, and HPV18 E6) to bind A9UPE9 PDZ and DLG1 PDZ 1 equally tightly
and were surprised that was not the case. We also expected SRRTEV and STRSDV to bind to
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A9UPE9 PDZ to some appreciable degree. However, an analysis of differences in binding
between these peptides may explain these outcomes.
The P-1 position seems to be a crucial determinant of binding affinity. In fact, when we
look at the structure of DLG1 PDZ1 aligned with a homology model of A9UPE9 PDZ, we see a
lysine on A9UPE9 PDZ at the position that would directly be interacting with the P-1 position
(Figure 9A). This lysine is more likely to interact with a negative residue, like an aspartic acid,
than with a threonine, which explains why SRETTV and RRETTV bound less tightly to
A9UPE9 PDZ than SRETDV and RRETDV.
At the P-3 position, SRRTEV and STRSDV both have an arginine, while the six other
peptides discussed here and shown in Table 3 have a glutamic acid. Given the charge difference
between these two residues, I initially thought an electrostatic interaction might be abolishing
peptide binding. Upon closer inspection of the homology this does not appear to be the case. The
homology model does, however, reveal that steric hindrance might be impacting the binding of
these two peptides to A9UPE9 PDZ (Figure 9B). The arginine residue, though flexible, is, in the
conformation shown here, directly contacting the PDZ domain. This suggests that, at least in
certain conformations, the arginine residue is too large to fit into the binding cleft.
Furthermore, we hypothesize that the P-5 position is interacting with the variable loop of
these PDZ domains (Figure 9C). In A9UPE9 PDZ, the residue on the variable loop positioned to
interact with the peptide is an aspartic acid, whereas in DLG1 PDZ1 it is an asparagine. The
aspartic acid is most likely interacting with the arginine of RRETTV and RRETDV more than
the serine of SRETTV and SRETDV, possibly explaining the difference in binding affinity
between peptides with a variation at the P-5 position.
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Figure 9. (A) P-1 interaction with A9UPE9 PDZ and DLG1 PDZ1 (PDB ID: 3RL7) colored by heteroatom (O=red
N=blue). A9UPE9 PDZ lysine shown in cyan stick and DLG1 PDZ1 shown in salmon stick. Peptide (RRETQV
from PDB ID: 2OQS) shown in orange stick and colored by heteroatom. Measurements between PDZ domains and
glutamine at P-1 labeled. (B) Variable loop of A9UPE9 PDZ and DLG1 PDZ1 colored by heteroatom. A9UPE9 PDZ
aspartic acid shown in cyan stick and DLG1 PDZ1 asparagine shown in salmon stick. Peptide (KKETPV) P-5
position shown in orange stick and colored by heteroatom. Measurements between these interacting residues are
labeled.

1.2.3 Structural and biochemical characterization of A9V7X5 PDZ.
Another M. brevicollis protein of interest was A9V7X5 (Figure 10). This protein is 1213
amino acids in length and contains both a PDZ domain (residues 709-790) and a Src-homology 2
(SH2) domain (residues 540-649). A9V7X5 PDZ is unique because of the combination of PDZ
and SH2 domain. These two protein domains do not, to our knowledge, exist in the human
proteome together in the absence of other protein domains. Furthermore, SH2 domains are
responsible for phosphorylated tyrosine (pTyr) signaling, largely in protein tyrosine kinase
pathways. It is interesting that two domains responsible for different signaling pathways exist
concurrently in this M. brevicollis protein.
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Figure 10. Alignment of A9UPE9 PDZ, shown in cyan, and A9V7X5 PDZ, shown in limon, homology models with
seven binding site residues highlighted. Sequence alignment of A9UPE9 PDZ and A9V7X5 PDZ with seven
binding site residues highlighted.

Table 4. Sequence identity values of A9V7X5 PDZ and human PDZ domains.

GRD2I-1

SI1L1

WHRN-2

GRIP2-2

RHPN-1

PTN13-4

PZRN4-2

MPDZ-1

LNX2-3

A9V7X5
PDZ

PDZ3 ZO3

Sequence percent identity

31.75%

31.51%

30.65%

30.26%

29.87%

29.73%

28.95%

28.57%

28.21%

28.21%

A9V7X5 PDZ shows the most sequence similarity to the third PDZ domain of human
ZO3 with 31.75% identity (Table 4). However, Domain Analyzer found similarities in the seven
critical binding site residues that provided different results (Table 5). Domain Analyzer found
Rhophilin-1 (RHPN-1) PDZ to be most similar to A9V7X5 PDZ in those seven binding site
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locations with a 32% alignment score (Figure 11). Based on these alignment scores, I was able to
do a literature search to ascertain the peptide sequence of some of these high identity match
proteins. This search yielded proteins SCARB1, SLC26A6, and SLC9A3 with peptide sequences
GGGTGS, VSVTRL, and PESTHM, respectively. Inputting these sequences into Motif Matcher
generated a host of endogenous sequences that could be further studied (Table S 3). Structural
and biochemical characterization of A9V7X5 PDZ is ongoing.

Table 5. Domain Analyzer identity results of A9V7X5 PDZ.

PDZ2 Whirlin

PDZ3
NHE-RF3

PDZ 3
PDZK1P1

SHANK1

SHANK2

MPP2/p55

MAGIX

PDZ2
NHE-RF1

MAST4

A9V7X5
PDZ

Rhophilin-1

Alignment Score % (identity matches/characteristic matches)

32%
(4/1)

28%
(4/1)

23%
(4/0)

23%
(4/0)

21%
(4/0)

21%
(4/0)

30%
(4/0)

29%
(4/0)

26%
(3/2)

26%
(3/2)

Figure 11. Homology model of alignment of A9V7X5 PDZ, with binding site residues shown in limon, and
homology model of RHPN-1 PDZ, with binding site residues shown in magenta.
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1.3 Concluding Remarks
Structural and biochemical characterization of non-homologous PDZ domains may
provide some of the necessary information to decipher the role of signaling and trafficking
pathways in the evolution of the metazoan lineage. By comparing the peptide-binding clefts of
humans and our closest non-metazoan ancestor, the choanoflagellate, we can begin to unravel
some of the features that may have developed after metazoan and choanoflagellate divergence.
Protein-protein interactions involving PDZ domains play a critical role in cellular signaling and
trafficking both in humans and choanoflagellates. Interestingly, there are many M. brevicollis
PDZ domain-containing proteins that have a unique domain architecture compared to humans.6
As discussed in this chapter, A9UPE9 has an SH3 domain and a PDZ domain, while A9V7X5
has a SH2 domain and a PDZ domain (one of five proteins in the M. brevicollis genome with this
architecture). Studying those PDZ domains that exist in M. brevicollis proteins with distinct
domain architecture may provide insight into unique signaling pathways in the choanoflagellate.
Specifically, investigating selectivity determinants of choanoflagellate PDZ domains can help us
glean a deeper understanding of their function. Here, we used DAMM to better understand the
selectivity of an uncharacterized PDZ domain, A9UPE9.
DAMM is a powerful tool to help analyze uncharacterized choanoflagellate PDZ
domains in the context of human PDZ domains. This program not only matches PDZ domains by
the residues on the domain interacting with non-motif residues on the peptide, but also generates
a high match human PDZ domain so we can, through literature search, find human targets of that
domain. Motif Mather then finds homologs to those peptide sequences in the M. brevicollis
proteome. These two parts of this program come together to find endogenous M. brevicollis
targets relatively quickly. By narrowing down the proteome to only a handful of potential
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cellular targets, it becomes much easier to ascertain the function of these uncharacterized PDZ
domains.
Theoretically, any conserved protein domain could utilize this program to predict binding
partners. If the structure of the peptide binding cleft was highly conserved, a database of labeled
protein sequences would need to be generated to create a sufficient base from which the program
can pull. The binding site residues of interest would be different, so DAMM would need to be
modified to account for variation in the number of residues. By making these changes, DAMM
could be tailored to output alignment scores in another type of peptide-binding domain. Motif
Matcher could then be applied, given the proteome of the uncharacterized protein domain is
available. Thus, DAMM is a program that has merits not only for PDZ domains, but potentially
for any structurally conserved peptide-binding domain.
It would be interesting not only to use this program for other peptide-binding domains,
but also in different organisms. Other ancestral unicellular eukaryotes such as S. rosetta and C.
owczarzaki, both of whom have a proteome in UniProt, would be interesting candidates. Using
this methodology to analyze specificity of peptide-binding domains is significantly less laborious
than other methods of finding protein binding partners and has the added benefit of focusing on
endogenous sequences. This allows us to understand not only the binding specificity, but the role
the protein may play in the organism. For non-homologous proteins specifically, this may help
reveal some differences during choanoflagellate and metazoan divergence that play a role in
multicellularity and the evolution of more complex signaling networks. Using tools like those
described herein to investigate the binding selectivity for individual domains both in uni- and
multicellular organisms is a powerful way to build a better understanding of signaling networks
and more holistic views of the evolution of multicellularity.
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1.4 Materials and Methods
1.4.1 Protein Expression and Purification.
Expression and purification of all human and M. brevicollis PDZ domains followed a
similar protocol as previously reported for mbSHANK1 PDZ.13 N-terminally His-tagged
versions of the PDZ domains with a cleavable TEV site were inserted into the pET28a+ vector
by gene synthesis (GenScript) and expressed in Escherichia coli BL21 (DE3) cells. Cells were
lysed on ice using sonication. The lysis buffer used was: 50 mM Tris pH 8.5, 200 mM NaCl, 10
mM CaCl2, 10 mM MgCl2, 20% (w/v) glycerol, 50 mM imidazole pH 8.5, 0.25 mM TCEP,
DNAse, and protease inhibitor cocktail. Immobilized metal-affinity chromatography (5 mL
HisTrap (GE Healthcare)) was used to purify proteins from the clarified supernatant. The wash
buffer used was: 25 mM imidazole pH 8.5, 25 mM Tris pH 8.5, 250 mM NaCl, 10% (v/v)
glycerol, and 0.25 mM TCEP, and elution buffer was: 400 mM imidazole pH 8.5, 25 mM Tris
pH 8.5, 50 mM NaCl, 10% (v/v) glycerol, and 0.25 mM TCEP. Except for the protein used in
binding experiments, the protein was then dialyzed in dialysis buffer (same as gel filtration
buffer described below) and incubated at 4°C overnight with TEV protease to cleave off the Histag. The cleaved protein was then purified using a second nickel column with the wash and
elution buffers described above. All proteins were further purified on a Superdex S75 column,
using gel filtration buffer (25 mM Tris pH 8.5, 150 mM NaCl, 10% (w/v) glycerol, 0.5 mM
TCEP). Proteins were concentrated using Amicon centrifugal concentrators (3 MWCO).
Concentrated proteins used in fluorescence polarization assays were flash frozen in liquid
nitrogen for storage at -80°C. Proteins used for crystallization were stored at 4°C. A9UPE9 PDZ
was quantitated with the A280 and the experimental extinction coefficient value of 1490 cm1

*M-1.
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1.4.2 Crystallization and Data Collection.
Prior to crystallization, all PDZ domains were dialyzed into a crystallization buffer (25
mM NaCl, 10 mM Hepes pH 7.4) for 2 hours. The protein concentration used for crystallization
of A9UPE9 PDZ was 12 mg/mL. Peptide was added at a final concentration of 1 mM and
incubated with protein for 1 hour prior to crystallization. HPV16 E6 was used for A9UPE9 PDZ.
Initial crystallization conditions were identified using the PEG/Ion screen (Hampton Research).
The crystallization conditions of crystals used for data collection were: A9UPE9 PDZ [20mM
sodium fluoride, 20% (w/v) PEG 3350] (Figure 12).

Figure 12. Crystals of A9UPE9 PDZ.

For data collection, crystals were transferred into cryoprotectant buffer. For A9UPE9
PDZ, 20% (w/v) glycerol was added directly to the respective PEG/Ion screen solution. The
crystals were flash-cooled by plunging into liquid nitrogen. Data was collected at the Advanced
Light Source (ALS) at the Lawrence Berkeley National Laboratory (LBNL) on beamline 5.0.1,
at λ=0.977410 Å over 360°, with ∆φ=0.25° frames and an exposure time of 0.5 s per frame.
Molecular replacements have so far been unsuccessful, but studies are ongoing.
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1.4.3 Binding assays by fluorescence polarization.
Fluorescence polarization assays were performed as previously described.12,13,15,19
Replicate experiments were performed to determine the KD values of A9UPE9 PDZ (N=3) and
DLG1-1 for the fluorescence peptide, F*-HPV18 E6 (FITC-RLQRRETQV). For A9UPE9 PDZ
we determined a KD value of 6.9 ± 1.7 µM for F*-HPV18 E6 (Figure 8C). For DLG1 PDZ1 we
determined a KD value of 2.3 ± 1.6 (Figure 8D).
Competition experiments: The final protein concentrations for Ki experiments were equal
to: 10.5 µM for A9UPE9 PDZ and 4.5 µM for DLG1 PDZ1. Competition experiments were
performed in triplicate, using F*-HPV18 E6 as a reporter peptide at 30 nM final concentration.
Binding affinities for Ki experiments were determined using SOLVER, as previously
described.12–14
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Chapter 2: Structural characterization of DLG homolog Monosiga brevicollis A9UT73
PDZ2
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2.1 Results: Structural characterization of PDZ domains in mbDLG
We also wanted to investigate multiple PDZ domains from a single M. brevicollis
protein. Therefore, we experimentally determined the structures of PDZ2 and PDZ3 from
UniProt ID A9UT73_MONBE (Table S 6). This protein is most closely related to the discs large
family of human proteins. Sequence identity values for the full-length protein are as follows:
human Dlg1 (35.5%), Dlg2 (35.0%), Dlg3 (34.1%), and Dlg4 (30.5%). We will refer to these
PDZ domains as mbDLG-2 and mbDLG-3, respectively. The highest domain-to-domain identity
for both mbDLG-2 and mbDLG-3 is to PDZ2 and PDZ3 of human Dlg2 (Figure S 1A).
Expression, purification, and crystallization of mbDLG-2 was performed as described in
the Materials and Methods and Supplementary Information, and followed similar protocols as
described in this work and elsewhere.12,13 Interestingly, the sequence of mbDLG-2 contains zero
aromatic residues, and thus has an extinction coefficient at λ = 280 nm of 0. Therefore, protein
quantification for crystallization was done via SDS-PAGE analysis using BSA as a standard, as
described in the Materials and Methods and Supplementary Information (Figure S 1B). Because
we were not confident in our precise determination of the mbDLG-2 concentration, we chose not
to calculate any binding affinities for this domain. However, sequence and structural similarities
(described below) suggest that this domain will bind similar peptides as human Dlg2 PDZ2. For
structure determination by X-ray crystallography, the mbDLG-2 protein was incubated with a
peptide matching the final 10 residues of the HPV16 E6 oncoprotein (sequence: SSRTRRETQL)
prior to crystallization and crystallized in two distinct space groups, differing in the ability to
accommodate a peptide in the crystal lattice: P 21 21 21 and I 2 (which is related to C 2).20 A
structure of human Dlg2 PDZ2 (or DLG2-2, PDB ID: 2BYG) was successfully used as a search
model in molecular replacement for both crystal forms.
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The mbDLG-2 structure is similar in both crystal symmetries. The overall RMSD is
0.153 Å for 300 main chain atoms (Figure 13A). We are unable to resolve an additional 6 Cterminal residues in the orthorhombic (P 21 21 21) crystal, which form an α-helix in our other
monoclinic structure (described below), but there is positive density in the peptide-binding cleft
that likely corresponds to the HPV16 E6 peptide (Figure S 1C). Iterative rounds of refinement
after placing peptide residues into this density confirm that there may be multiple confirmations
of the peptide within the pocket and that its occupancy is likely 0.50 or less. This caused a lack
of confidence in modeling the peptide residues in the final structure. In the centered monoclinic
(I 2) crystal, we can resolve the entire βA-βB loop; however, crystal contacts with molecules
related by symmetry are not compatible with peptide binding (Figure S 1D).
The major difference between these two structures is the location of the carboxylatebinding loop, a shift that is consistent with carboxylate-binding loop flexibility in several apo
and peptide-bound structures of human Dlg2 PDZ2 (Figure 13A and Figure S 1E). Finally,
comparison with the peptide binding cleft of human Dlg2 PDZ2 (PDB ID: 4G69) reveals only
two relatively conservative differences (using human Dlg2 PDZ2 numbering): N339S and
K392R (Figure 13B).
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A

B

Figure 13. The crystal structure of the mbDLG-2 PDZ domain. (A) Alignment of the two mbDLG-2 structures,
which crystallized in different space groups: I 2 (purple cartoon) and P 21 21 21 (gray cartoon). Overall RMSD =
0.153 Å for 300 main chain atoms. The biggest difference between the structures is a shift in the carboxylatebinding loop, indicated by a black arrow. (B) The conservation between the peptide binding clefts of mbDLG-2
(purple cartoon, with side chain residues as sticks) and human DLG1 PDZ2 (PDB ID: 4G69, gray cartoon with side
chain residues as sticks and peptide as ribbon and labeled). Residues in the peptide-binding cleft are labeled. All
stick representation is colored by heteroatom (O = red, N = blue).

28

Figure 14. Crystal of mbDLG-2 with HPV16 E6.
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2.2 Concluding Remarks
Structural comparison of the peptide-binding clefts and peptide interactions of
homologous domains from organisms related by hundreds of millions of years of evolution has
the potential to provide insight into signaling networks in those species. Here, we chose to use
structural biology and biochemistry to investigate PDZ domain-containing proteins that are
important in human neuronal signaling in a species of choanoflagellates, our closest nonmetazoan ancestors. Many of the human targets of the Dlg family (including PSD-95) are either
not conserved in choanoflagellates or do not contain PDZ binding sequences.13 However, we
find that the peptide binding-cleft residues for human and/or choanoflagellate peptides are
generally conserved in these related domains.
Our structures of this unique M. brevicollis PDZ domain provides one of the first
structural determination of choanoflagellate PDZ domains to our knowledge. Our comparisons
with known human PDZ domain structures, as well as homology and Rosetta modeling confirm
that because the PDZ domain fold is well conserved, it is possible to get an initial idea of a PDZ
domain structure without experimental structure determination. For example, we can use
homology modeling with the closest-related human PDZ domains by sequence identity, to
propose the structures of mbDLG-1 (template: INADL-8 [PDB ID: 2DM8], 49.3% identical over
69 residues).
We can also propose the structures of PDZ domains that are in proteins with no obvious
relation to human proteins, aside from the presence of one or more known domains, for example,
A9VDV9_MONBE, which contains 1 PDZ and 1 Kinase domain (according to UniProt). The
highest sequence identity of this protein to any human protein, using BLASTP, is to the ROR2
tyrosine kinase receptor, at 26.53% over the kinase domain residues. The human ROR2 receptor
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does not contain a PDZ domain. As a template, we used the PARD3-2 PDZ domain structure
(PDB ID: 2KOM), which is 38.2% identical to the PDZ domain in A9VDV9_MONBE over 68
residues (Figure 15). This is of particular interest considering that a large majority of the M.
brevicollis PDZ domains are present in proteins with unique domain architecture, as compared to
human PDZ proteins (Figure 2). For example, there are no human PDZ domains in proteins that
also contain pTyr-binding SH2 signaling domains; however, in M. brevicollis, there are five PDZ
and-SH2-containing proteins (Figure 2, Table S 5).7 In addition, there are no human PDZ
domain-containing proteins with more than one guanylate kinase domain, but in M. brevicollis,
there are two, including a protein with four guanylate kinase domains, as annotated by UniProt
(Figure 2).7

Figure 15. Homology model for A9VDV9_MONBE (template: 2KOM). Left figure: a cartoon representation of the
model, with the αB‐1 residue and carboxylate‐binding loop side chains shown as sticks, as labeled. Middle figure: a
cartoon rainbow‐colored depiction that highlights conserved secondary structural elements. Right figure: a cartoon
hydrophobicity‐colored (with side chain sticks, residues colored by hydrophobicity) structure. The hydrophobicity
plots confirm that the PDZ fold is reasonable for each of these sequences (i.e., hydrophobic residues in the protein
core (indicated by darker red color) and hydrophilic/polar residues on the surface (indicated by pink or white color).
A9VDV9 left side figure colored hot pink. All sticks are colored by heteroatom: O = red, N = blue, S = yellow.
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We hypothesize that these types of analyses can be applied to PDZ domains from
multiple organisms related by evolution. Protein–protein interactions that involve PDZ domains
act as critical nodes for signaling and trafficking pathways in a cell. It is clear this is true in
differentiated cells, such as those in complex multicellular organisms, as well as in single-celled
organisms. Deciphering the PDZ-mediated interactions in choanoflagellates may elucidate
important characteristics of the selectivity determinants and the evolution of this important
peptide-binding domain. Furthermore, there are several proteins and protein architectures that
contain PDZ domains in choanoflagellates that are not conserved in humans. Future work could
investigate how these proteins, for example A9VDV9 mentioned above, act in signaling
pathways in M. brevicollis and how this provides insight into the transition from uni- to
multicellular life on Earth. Taken together, we suggest that investigating the structure–function
relationship for individual domains in both uni- and multicellular organisms is an important
component in building a holistic understanding of the signaling networks of an organism and in
understanding the origin of multicellularity.
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2.3 Materials and Methods
2.3.1 Protein expression and purification
Expression and purification of all human and M. brevicollis PDZ domains followed a
similar protocol as previously reported for mbSHANK1 PDZ13. His-tagged versions of the PDZ
domains were inserted into the pET28a (+) vector by gene synthesis (GenScript) and expressed
in Escherichia coli BL21 (DE3) cells. Cells were lysed using sonication then immobilized metalaffinity chromatography (5 mL HisTrap [GE Healthcare]) was used to purify proteins from the
clarified supernatant. The wash buffer used was: 25 mM imidazole pH 8.5, 25 mM Tris pH 8.5,
250 mM NaCl, 10% (w/v) glycerol, and 0.25 mM TCEP. The elution buffer was: 400 mM
imidazole pH 8.5, 25 mM Tris pH 8.5, 50 mM NaCl, 10% (w/v) glycerol, and 0.25 mM TCEP.
The protein was then dialyzed in dialysis buffer (25 mM Tris pH 8.5, 150 mM NaCl, 10% (w/v)
glycerol, and 0.5 mM TCEP) and incubated with PreScission protease to cleave off the His-tag.
The cleaved protein was then purified using a second nickel column with the wash and elution
buffers described above. The protein was further purified on a Superdex S75 column, using gel
filtration buffer (same as dialysis buffer described above). Protein was concentrated using
Amicon centrifugal concentrators (3 MWCO). Proteins used for crystallization were stored at
4°C. Due to an extinction coefficient of 0 cm−1 *M−1 mbDLG-2 PDZ protein was quantified
using an SDS-PAGE gel with BSA standards (Figure S 1B). As a result of the gel being
overloaded, the exact concentration of mbDLG-2 PDZ used for crystallization was not
determined, but I approximated the concentration to be 12.5–25 mg/mL.
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2.3.2 Crystallization, data collection, and structure determination
Prior to crystallization, all PDZ domains were dialyzed into a crystallization buffer (25
mM NaCl, 10 mM Hepes pH 7.4) for 2 hours. The mbDLG-2 concentration used for
crystallization was 12.5-25 mg/mL (see above). Peptide HPV16 E6 was added at a final
concentration of 1 mM and incubated with protein for 1-hr prior to crystallization. All initial
crystallization conditions were identified using the PEG/Ion screen (Hampton Research). The
crystallization conditions of crystals used for data collection were: mbDLG-2 in I 2 space group
(100 mM sodium malonate pH 5, 12% [w/ v] PEG 3350) and mbDLG-2 in P 21 21 21 space group
(200 mM sodium malonate pH 5, 20% [w/v] PEG 3350). For data collection, crystals were
transferred into cryoprotectant buffer. For mbDLG-2, 15% (w/v) glycerol was added directly to
the respective PEG/Ion screen solution. The crystals were flash-cooled by plunging into liquid
nitrogen. Data were collected at the Advanced Light Source (ALS) at the Lawrence Berkeley
National Laboratory (LBNL) on beamline 5.0.1, at λ = 0.977410 Å over 360, with Δϕ = 0.25
frames and an exposure time of 0.5 s per frame. Data were processed using the XDS package
(Table S 6).21–23 Molecular replacement was performed using Phenix with the search models
2BYG, human DLG2 PDZ2.24,25 Refinement was performed using Phenix, manual refinement
was done using Coot, and model geometry was assessed using Molprobity and the PDB
validation server.24–30 All crystal data and refinement statistics are in Table S 6. PDB accession
codes for the structures presented here are: 6X1P (mbDLG-2, spacegroup I 2) and 6X1R
(mbDLG-2, spacegroup P 21 21 21).
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Chapter 3: A study of homologous TEC family kinase SH2 domains
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3.1 Introduction: TEC family kinases and Src Homology 2 domains
Protein tyrosine kinases are a family of enzymes that transfer the gamma (𝛾𝛾) phosphate of

ATP to tyrosine residues on protein substrates (Figure 16). This phosphorylation can cause

changes in function and enzymatic activity, which result in specific biological responses that
create binding sites for the recruitment of downstream signaling proteins. De-regulation and/or
overexpression of these tyrosine kinases has been implicated in carcinogenesis.31

Figure 16. TEC family kinase activation and downstream signaling outcomes. Phosphorylation of the TEC family
kinase by Src kinase shown with red star.

The human genome contains 518 protein kinase genes (~1.7% of total genes) of which
17% are tyrosine kinases.31 Tyrosine kinases are subdivided into receptor tyrosine kinases
(RTKs) and non-receptor tyrosine kinases (NRTKs). NRTKS are subdivided into nine families
based on similarities in domain structure. Of the nine mammalian families of NRTKs, the TEC
family is the second largest, consisting of five members: Bruton’s tyrosine kinase (BTK),
inducible T-cell kinase (ITK), tyrosine kinase expressed in hepatocellular carcinoma (TEC),
bone-marrow expressed kinase (BMX), and resting lymphocyte kinase (RLK). These TEC
family kinases (TFKs) are widely expressed in hematopoietic tissues and mutations in Btk
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specifically can result in X-linked agammaglobulinemia.31,32 TFKs are distinguished by a
pleckstrin homology (PH) domain and a proline-rich region (Figure 17).31

Figure 17. (A) Major families of NRTKs with the TEC family in yellow. (B) Domain architecture of TEC family
kinases with domain legend below.

Src-homology 2 (SH2) domains are found in, and serve in the context of, tyrosine
kinases, phosphatases, actin cytoskeletal regulators, transcriptional activators, and more to
coordinate specific responses to distinct pTyr signaling events. A total of 121 SH2 domains are
known to be expressed in the human proteome, with 111 SH2 domain-containing genes. SH2
domains have an evolutionarily conserved phosphopeptide binding site that binds to pTyrcontaining peptide ligands with 1000 times greater affinity than their non-phosphorylated
counterparts.33
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Figure 18. Guide tree of several human SH2 domain-containing proteins.

Structurally, SH2 domains are about 100 amino acids long, with a core anti-parallel βsheet interposed between two ⍺-helices followed by another triple-stranded β-sheet on the C-

terminus. Binding occurs when a negatively charged phosphate moiety on tyrosine inserts into a
pocket in the B-sheet where an invariant arginine at position βB5 at the base of the pocket, with
arginine ⍺A2 and histidine βD4, coordinate the oxygen atoms of the phosphate moiety. Mutation
of either this arginine or histidine abolishes pTyr-specific binding.33 Specificity of the SH2

domain is determined through interactions with pockets on the surface of the SH2 domain that
recognize the residues located primarily C-terminal to the pTyr, but in various cases extending
from the P-2 position to the P5 with respect to the pTyr.34
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Figure 19. (A) Cartoon structure of the Src SH2 domain with ⍺-helices and 𝛽𝛽-strands labeled. pTyr peptide is

bound and shown in orange stick (PDB ID: 1SPS) (B) Btk phosphate moiety and coordinating residues.

Another pocket, the “specificity pocket”, is formed by the EF (which connects β strands
E and F) and BG (which connects ⍺-helix B and β-strand G) loops.33 These loops are usually

responsible for contacting the residues C-terminal to the pTyr and are more variable in sequence
than the rest of the SH2 domain. Despite these variations, these loops are identifiably conserved
from early invertebrates to humans, suggesting the specificity of SH2 domains may be fixed
relatively early in evolution, while the ligands themselves continue to evolve. The peptide
binding cleft is, however, not highly conserved, implying some degree of flexibility in those
residues.
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Figure 20. Multiple sequence alignment of SH2 domains with EF and BG loops highlighted in grey.

Initially, I wanted to investigate the non-motif selectivity determinants of TEC family Src
Homology 2 (SH2) domains. In PDZ domains, we know that non-motif selectivity determinants
play a crucial role in dictating the specificity of peptide binding to a PDZ domain. In PDZ
domains, every interaction between a peptide and a binding cleft residue matters for the overall
binding affinity of the ligand to the protein. I wanted to know if this extends to a domain where
the majority of binding is dictated by a phosphotyrosine (pTyr). In TEC family kinases, this pTyr
binds on order of 1000 times higher affinity than it’s unphosphorylated counterpart. However, if
this pTyr were the only factor that influenced binding specificity, then every pTyr in the body
would bind to this SH2 domain, making it neither high selectivity nor specificity. In fact,
different SH2 domains prefer different sequence motifs C-terminal to the pTyr. Characterizing
these different motifs and their effects on binding forms the crux of this project.
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3.2 Results: TEC Family Kinase SH2 Domain Expression and Purification
The first SH2 domains that we ordered had a frameshift mutation, resulting in a
premature stop codon and no histidine tag. This made the protein not only the incorrect length
(only 20 amino acids), but also incapable of binding to the nickel resin. The second time we
ordered these proteins, they had a histidine tag but were still not purifying correctly. UniProt,
unfortunately, cuts off the SH2 domain seven amino acids early on the N-terminus, which causes
the domain not to express and purify.

Figure 21. (A) Missing N-terminal residues of human Btk SH2 domain, denoted by yellow arrow. (B) 15% SDSPAGE gel of human Btk SH2 domain with SUMO tag (MW: 24.7 kDa).
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After correcting these issues, I was able to express and purify human Btk SH2 (Figure
21). At this point, it became clear through sequence analysis (Figure 20) that these loops are
similar enough that we would not predict SH2 domain selectivity to vary significantly between
the five SH2 domains I was studying. Thus, there would be no differences in binding selectivity
to analyze.
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3.3 Concluding Remarks: Future Directions
SH2 domains, like PDZ domains, have a high degree of structural conservation.
Accordingly, the same studies that I performed here on non-homologous PDZ domains and
previously on homologous PDZ domains could be conducted on SH2 domains in the
choanoflagellate.6 The TEC family kinases in humans are associated with the immune system
and hematopoietic function. Despite seemingly no need for a protein that serves this function, a
homolog of the TEC family kinases exists in M. brevicollis (UniProt ID: A9UXP1). Like the
TEC family kinases, A9UXP1 has a PH, SH3, SH2, and kinase domain. With no immune
system, the purpose of this protein is somewhat of a mystery and could be the subject of future
work using a similar methodology previously described for PDZ domains.13 Briefly, an analysis
of the sequence of A9UXP1 could be done in comparison to human TEC family kinases to assess
the residues in the EF and BG loops. Then, these residues could be compared to human SH2
domains to find the highest degree of homology. The binding partners of this human SH2
domain could be assumed to be similar to the binding partners of the M. brevicollis SH2 domain.
Motif Matcher could then be used to find homologous sequences of these binding partners in the
choanoflagellate proteome. Thus, likely binding partners of A9UXP1 could be found, which may
give information about the function A9UXP1 serves in the choanoflagellate.
Furthermore, because SH2 domains evolved alongside tyrosine phosphorylation, the SH2
domain of A9UXP1 may be one of the closest non-metazoan SH2 domains to humans and one of
the earliest SH2 domains to evolve. Their emergence during eukaryotic evolution may implicate
SH2 domains and tyrosine phosphorylation overall as vital in the creation of complex signaling
pathways that allowed multicellularity to develop robustly.
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A sequence alignment of A9UXP1 with human TEC family kinases shows a high degree
of homology in the EF and BG loops (Figure 22). While there are some differences, overall, we
would expect these domains to have similar binding selectivity. The high degree of homology
could allow this method to be successful in predicting binding partners for A9UXP1 and could
consequently help illuminate the function of A9UXP1 in the choanoflagellate.

Figure 22. (A) Sequence alignment of A9UXP1 with human TEC family kinase SH2 domains. (B) Homology
model of A9UXP1 and human Btk SH2 (PDB ID: 2GE9) with EF and BG loops colored in pink for A9UXP1 and
teal for human Btk SH2.
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3.4 Materials and Methods: Protein expression and purification
Expression and purification of all human, M. brevicollis and H. vulgaris SH2 domains
followed a similar protocol as previously reported for mbSHANK1 PDZ. 13 SUMO-tagged
versions of the SH2 domains were inserted into the pET28a (+) vector by gene synthesis
(GenScript) and expressed in Escherichia coli BL21 (DE3) cells. Cells were lysed using
sonication then immobilized metal-affinity chromatography (5 mL HisTrap [GE Healthcare])
was used to purify proteins from the clarified supernatant. The wash buffer used was: 25 mM
imidazole pH 8.5, 25 mM Tris pH 8.5, 250 mM NaCl, 10% (w/v) glycerol, and 0.25 mM TCEP.
The elution buffer was: 400 mM imidazole pH 8.5, 25 mM Tris pH 8.5, 50 mM NaCl, 10% (w/v)
glycerol, and 0.25 mM TCEP. The protein was then dialyzed in dialysis buffer (25 mM Tris pH
8.5, 150 mM NaCl, 10% (w/v) glycerol, and 0.5 mM TCEP) and incubated with ubiquitin-likespecific protease 1 to cleave off the SUMO-tag. The cleaved protein was then purified using a
second nickel column with the wash and elution buffers described above. The protein was further
purified on a Superdex S75 column, using gel filtration buffer (same as dialysis buffer described
above). Protein was concentrated using Amicon centrifugal concentrators (3 MWCO). Proteins
used for crystallization were stored at 4°C. For all SH2 domains, protein was quantitated with the
A280 and the experimental extinction coefficient values of: 12950 cm−1*M−1 for Tec from M.
brevicollis and Tec from H. vulgaris, 18910 cm−1*M−1 for Itk and Tec from human, and 17420
cm−1*M−1 for Btk from human.
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Supplemental Information
Table S 1. A9UPE9 PDZ Motif Matcher results with input motif highlighted in light teal. Results were filtered by
position constraints S/T for P-2 and F/I/L/V for P0. “subs” is the number of substitutions from the search sequence.
“match” is the match protein name. “matchSeq” is the match sequence. “src” is the search sequence.
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Table S 2. A9UPE9 and DLG1 PDZ1 Ki values for all peptides tested.

†

Standard deviations not reported for Ki values >1000 μM
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Table S 3. A9V7X5 PDZ Motif Matcher results with input motif highlighted in light green. Results were filtered by
position constraints S/T for P-2 and F/I/L/V for P0. “subs” is the number of substitutions from the search sequence.
“match” is the match protein name. “matchSeq” is the match sequence. “src” is the search sequence.
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Table S 4. Indexed PDZ domains for Domain Analyzer.
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Table S 4. (continued)
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Table S 5. Monosiga brevicollis PDZ domains with highest human match and domain architecture shown.
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Table S 5 (continued)
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Table S 5 (continued)
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Table S 6. Data collection and refinement statistics.
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Figure S 1. Sequence alignment of Dlg proteins, mbDLG‐2 structures, and human Dlg2 PDZ2 structures. (A)
Sequence alignment of PDZ domains from human DLG1‐4 and mbDLG proteins. (B) Because mbDLG‐2 does not
contain any aromatic residues, and thus has an extinction coefficient equal to 0, we quantified the protein for
crystallization using SDS‐PAGE. A dilution series of bovine serum albumin (BSA) protein was added as a standard
and compared to mbDLG‐2protein used for crystallization, as labeled. The gel is overloaded, so we estimated the
protein concentration to be 12.5–25 mg/mL, which suggests that the density of our protein signal, on average, is
closest to the 12.5 and 25 μg BSA lanes. (C) The P 21 21 21 mbDLG‐2 PDZ domain (gray cartoon, electron density is
shown in blue mesh, 2Fo‐Fcmap contoured at 1 s) structure revealed strong positive density (green mesh, Fo‐Fcmap
contoured at 2.5 s, highlighted by the green circle) in the peptide binding cleft, which is likely the HPV16 E6
peptide that was incubated with the PDZ domain prior to crystallization; however, iterative rounds of refinement
suggested that the occupancies of peptide atoms were <0.5 and that there were multiple conformations. Ultimately,
the peptide could not be confidently modeled. A black arrow points to the carboxylate‐binding loop, which is
labeled. (D) The mbDLG‐2 PDZ domain (purple surface) that crystallized in the I 2 space group is not bound by
peptide, due to molecules related by symmetry (gray surface). The mbDLG‐2 PDZ domain was aligned with the
CAL PDZ domain structure bound to a HPV16 E6 peptide (PDB ID: 4JOP, RMSD = 0.859 Å for 239 main chain
atoms). Steric clashes between molecules related by symmetry and the HPV16 E6 peptide (yellow sticks and
labeled) are highlighted with red circles. (E) Comparison of the locations of carboxylate‐binding loop sequences for
a number of human Dlg2 PDZ2 structures, including those in the apo form (cyan cartoon) and peptide‐bound
structures (gray cartoon, with peptides as gray ribbons). PDB ID codes included are: 2AWW, 2AWX, 2G2L, 2I0L,
2M3M, 2OQS, 2X7Z, 4G69, 4OAJ.

62

Figure S 2. Hydrophobicity of choanoflagellate PDZ domains. (A) experimentally determined crystal structures
and (B) models determined by Rosetta or SwissModel. All PDZ domains, with experimentally determined structures
(A) or models of borderline sequences from our M. brevicollis proteome search (B) are labeled and shown in cartoon
representation, with side chain sticks. Coloring is by degree of hydrophobicity, using previously determined values.
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